Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy ; volume:12 ; number:1 ; day:22 ; month:6 ; year:2012 ; pages:1-16 ; date:12.2012
BMC cancer ; 12, Heft 1 (22.6.2012), 1-16, 12.2012
- Urheber
-
Gamarra-Luques, Carlos D.
- Beteiligte Personen und Organisationen
-
Goyeneche, Alicia A.
Hapon, Maria B.
Telleria, Carlos M.
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-12-200
- URN
-
urn:nbn:de:1111-201603042425
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gamarra-Luques, Carlos D.
- Goyeneche, Alicia A.
- Hapon, Maria B.
- Telleria, Carlos M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells
NIPEC with Single-Dose Intraperitoneal Cisplatin and Paclitaxel in Stage III Epithelial Ovarian Cancer
Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin
No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin
Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity
Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy
Escaping Nash inflation
Escaping Nazi atrocities
Escaping unemployment traps
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells
NIPEC with Single-Dose Intraperitoneal Cisplatin and Paclitaxel in Stage III Epithelial Ovarian Cancer
Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin
No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin
Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity
Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy
Escaping Nash inflation
Escaping Nazi atrocities
Escaping unemployment traps
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells
NIPEC with Single-Dose Intraperitoneal Cisplatin and Paclitaxel in Stage III Epithelial Ovarian Cancer
Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin
No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin
Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity
Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy
Escaping Nash inflation
Escaping Nazi atrocities